ALLO Stock Analysis: Buy, Sell, or Hold?
ALLO - Allogene Therapeutics, Inc. Common Stock
$2.05
0.07 (3.54%)
â˛
5d:
+1.99%
30d:
+14.53%
90d:
-4.21%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When ALLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ALLO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ALLO is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ALLO is currently trading at $2.05, which is considered slightly high relative to its 30-day fair value range of $1.80 to $2.06.
Technical Outlook: Technically, ALLO is in a downtrend. Immediate support is located at $1.81, while resistance sits at $2.19. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: ALLO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+339.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALLO is in a downtrend. Immediate support is located at $1.81, while resistance sits at $2.19. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: ALLO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+339.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.80 -
$2.06
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 339.0% below Wall St target ($9.00)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.80 -
$2.06
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.81
Resistance Level
$2.19
Current Trend
Downtrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.99
Wall Street Target
$9.00
(+339.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 16, 2026 2:40 AM ET
Data refreshes hourly during market hours. Next update: 3:40 AM
Data refreshes hourly during market hours. Next update: 3:40 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Annie Yoshiyama
SELL
9586 shares
2026-04-21
Benjamin Machinas Beneski
SELL
2867 shares
2026-03-31
Benjamin Machinas Beneski
SELL
4835 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 46 HOLD |
